RSCM
AGIO icon

Rock Springs Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Rock Springs Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27M Hold
799,163
– – 1.59% 19
2025
Q4 		$21.8M Sell
799,163
-159,379
-17% -$5.59M 1.12% 28
2025
Q3 		$38.5M Sell
958,542
-31,203
-3% -$1.17M 2.25% 12
2025
Q2 		$32.9M Buy
989,745
+647,565
+189% +$19.6M 2.05% 16
2025
Q1 		$10M Sell
342,180
-128,906
-27% -$4.28M 0.57% 51
2024
Q4 		$15.5M Sell
471,086
-228,303
-33% -$10.7M 0.59% 51
2024
Q3 		$31.1M Sell
699,389
-344,872
-33% -$15.7M 1.01% 39
2024
Q2 		$45M Sell
1,044,261
-720,244
-41% -$26M 1.36% 29
2024
Q1 		$51.6M Sell
1,764,505
-387,668
-18% -$10.4M 1.31% 29
2023
Q4 		$47.9M Sell
2,152,173
-557,888
-21% -$12.5M 1.18% 29
2023
Q3 		$67.1M Buy
2,710,061
+23,894
+0.9% +$632K 1.8% 17
2023
Q2 		$76.1M Buy
2,686,167
+24,562
+0.9% +$611K 1.81% 19
2023
Q1 		$61.1M Sell
2,661,605
-334,987
-11% -$8.9M 1.46% 24
2022
Q4 		$84.1M Sell
2,996,592
-61,277
-2% -$1.73M 2.02% 14
2022
Q3 		$86.5M Buy
3,057,869
+129,411
+4% +$3.47M 2.23% 12
2022
Q2 		$64.9M Buy
2,928,458
+263,183
+10% +$5.94M 1.89% 12
2022
Q1 		$77.6M Buy
2,665,275
+18,650
+0.7% +$570K 1.95% 12
2021
Q4 		$87M Buy
2,646,625
+90,446
+4% +$3.64M 2.01% 12
2021
Q3 		$118M Sell
2,556,179
-18,129
-0.7% -$876K 2.48% 6
2021
Q2 		$142M Buy
2,574,308
+30,708
+1% +$1.72M 2.8% 3
2021
Q1 		$131M Buy
2,543,600
+20,079
+0.8% +$994K 2.87% 1
2020
Q4 		$109M Buy
2,523,521
+942,012
+60% +$37.2M 2.32% 6
2020
Q3 		$55.4M Buy
1,581,509
+401,789
+34% +$17.6M 1.4% 20
2020
Q2 		$63.1M Buy
1,179,720
+124,220
+12% +$5.75M 1.73% 10
2020
Q1 		$37.4M Buy
1,055,500
+414,000
+65% +$19.1M 1.55% 18
2019
Q4 		$30.6M Buy
641,500
+289,000
+82% +$10.9M 0.97% 37
2019
Q3 		$11.4M Buy
352,500
+182,000
+107% +$7.53M 0.46% 68
2019
Q2 		$8.51M Buy
170,500
+53,000
+45% +$2.83M 0.31% 84
2019
Q1 		$7.92M Buy
+117,500
New +$6.84M 0.31% 92

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Rock Springs Capital Management's AGIO Position: Q1 2026 in Review

Rock Springs Capital Management held its Agios Pharmaceuticals (AGIO) position steady in Q1 2026 at 799,163 shares worth $27M. The position accounts for 1.59% of the portfolio, ranked #19.

Rock Springs Capital Management first reported a position in AGIO in Q1 2019 and has held it in 29 quarters since. The position peaked at $142M in Q2 2021. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Rock Springs Capital Management held 799,163 shares of Agios Pharmaceuticals worth $27M as of Q1 2026.
  • Rock Springs Capital Management left its Agios Pharmaceuticals share count unchanged in Q1 2026.
  • Agios Pharmaceuticals made up 1.59% of Rock Springs Capital Management's portfolio in Q1 2026, its #19 holding.
  • Rock Springs Capital Management first reported a position in Agios Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • Rock Springs Capital Management's Agios Pharmaceuticals position peaked at $142M in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.